Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares traded down 1.7% during mid-day trading on Monday . The company traded as low as $10.70 and last traded at $11.24. 1,354,564 shares changed hands during trading, an increase of 301% from the average session volume of 337,931 shares. The stock had previously closed at $11.43.
Silverback Therapeutics Stock Performance
The company’s 50 day moving average price is $12.77 and its 200-day moving average price is $12.68. The stock has a market cap of $409.62 million, a P/E ratio of -4.69 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- How Technical Indicators Can Help You Find Oversold Stocks
- How Do Stock Buybacks Affect Shareholders?
- What to Know About Investing in Penny Stocks
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
